Stocks
Funds
Screener
Sectors
Watchlists
AWH

AWH - Aspira Women's Health Inc. Stock Price, Fair Value and News

$0.79-0.02 (-2.47%)
Market Closed
Max Portfolio Pct.
Check
Valuation
Check

Stock Quality:

GPSDBMFI
Max Portfolio Pct.
Check
Valuation
Check
GPSDBMFI

AWH Price Action

Last 30 days

-9.0%


Last 90 days

-15.6%


Trailing 12 Months

-74.7%

AWH RSI Chart

AWH Valuation

Market Cap

13.5M

Price/Earnings (Trailing)

-0.91

Price/Sales (Trailing)

1.51

EV/EBITDA

-0.6

Price/Free Cashflow

-0.63

AWH Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

AWH Fundamentals

AWH Revenue

Revenue (TTM)

9.0M

Rev. Growth (Yr)

1.8%

Rev. Growth (Qtr)

-6.85%

AWH Earnings

Earnings (TTM)

-14.8M

Earnings Growth (Yr)

24.63%

Earnings Growth (Qtr)

-0.48%

AWH Profitability

EBT Margin

-213.27%

Return on Equity

587.1%

Return on Assets

-310.88%

Free Cashflow Yield

-158.03%

AWH Investor Care

Shares Dilution (1Y)

61.24%

Diluted EPS (TTM)

-1.16

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20249.0M8.9M9.0M0
20238.6M9.0M9.2M9.2M
20227.2M7.5M7.9M8.2M
20214.9M6.0M6.4M6.8M
20205.0M4.6M4.5M4.7M
20193.2M3.6M4.2M4.5M
20181.5M2.0M2.5M3.1M
2017477.0K632.0K787.0K942.0K
20161.7M1.9M2.2M322.0K
20153.2M3.4M3.4M2.2M
20142.5M2.5M2.5M2.5M
20132.1M2.1M2.1M2.6M
20121.8M1.8M1.8M2.1M
20111.4M1.5M1.7M1.9M
20100001.2M
AWH
Aspira Women's Health Inc., together with its subsidiaries, engages in developing and commercializing diagnostic tests for gynecologic disease in the United States. The company's products include Ova1, a blood test intended as an aid to further assess the likelihood of malignancy in women with an ovarian adnexal mass; Overa, a biomarker reflex test; and Ova1Plus, a reflex offering. Its product pipeline includes OvaWatch, a non-invasive blood-based risk assessment test to determine ovarian cancer risk for patients with an adnexal mass; and Endocheck, an in-development non-invasive blood test designed as an aid in the identification of endometriosis for patients with suspected endometriosis earlier in their prognosis journey. In addition, the company operates Aspira Synergy, a testing platform and cloud service; and owns and operates ASPiRA LABS, a lab that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and disease. The company serves physicians, physician office laboratories, and national and regional laboratories. The company distributes its products through its national sales force, its platform Aspira Synergy, and a marketing and distribution agreement with BioReference Health, LLC. It has a research agreement with Harvard Dana-Farber Cancer Institute, Brigham and Women's Hospital, and Medical University Lodz to evaluate the microRNA technology in combination with Aspira technologies for the development of an early detection test for ovarian cancer; and a strategic alliance with Quest Diagnostics, Incorporated. The company was formerly known as Vermillion, Inc. and changed its name to Aspira Women's Health Inc. in June 2020. Aspira Women's Health Inc. was incorporated in 1993 and is based in Austin, Texas.
 CEO
 WEBSITEhttps://aspirawh.com
 SECTORHealthcare
 INDUSTRYDiagnostics & Research
 EMPLOYEES85

Aspira Women's Health Inc. Frequently Asked Questions


What is the ticker symbol for Aspira Women's Health Inc.? What does AWH stand for in stocks?

AWH is the stock ticker symbol of Aspira Women's Health Inc.. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Aspira Women's Health Inc. (AWH)?

As of Wed Dec 04 2024, market cap of Aspira Women's Health Inc. is 13.5 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of AWH stock?

You can check AWH's fair value in chart for subscribers.

Is Aspira Women's Health Inc. a good stock to buy?

The fair value guage provides a quick view whether AWH is over valued or under valued. Whether Aspira Women's Health Inc. is cheap or expensive depends on the assumptions which impact Aspira Women's Health Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for AWH.

What is Aspira Women's Health Inc.'s Price to Earnings (PE) and Price to sales (PS) ratio?

As of Wed Dec 04 2024, AWH's PE ratio (Price to Earnings) is -0.91 and Price to Sales (PS) ratio is 1.51. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. AWH PE ratio will change depending on the future growth rate expectations of investors.

What is 5 year return on Aspira Women's Health Inc.'s stock?

In the past 10 years, Aspira Women's Health Inc. has provided -0.274 (multiply by 100 for percentage) rate of return.